OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Increased risk of cardiovascular events and death in the initial phase after discontinuation of febuxostat or allopurinol: another story of the CARES trial
Byeongzu Ghang, Ji Sung Lee, Jihye Choi, et al.
RMD Open (2022) Vol. 8, Iss. 2, pp. e001944-e001944
Open Access | Times Cited: 14
Byeongzu Ghang, Ji Sung Lee, Jihye Choi, et al.
RMD Open (2022) Vol. 8, Iss. 2, pp. e001944-e001944
Open Access | Times Cited: 14
Showing 14 citing articles:
Advances in pharmacotherapies for hyperuricemia
Federica Piani, Davide Agnoletti, Claudio Borghi
Expert Opinion on Pharmacotherapy (2023) Vol. 24, Iss. 6, pp. 737-745
Closed Access | Times Cited: 26
Federica Piani, Davide Agnoletti, Claudio Borghi
Expert Opinion on Pharmacotherapy (2023) Vol. 24, Iss. 6, pp. 737-745
Closed Access | Times Cited: 26
Ganoderma lucidumpolysaccharide peptide alleviates hyperuricemia by regulating adenosine deaminase and urate transporters
Simei Lin, Jia Meng, Fei Li, et al.
Food & Function (2022) Vol. 13, Iss. 24, pp. 12619-12631
Closed Access | Times Cited: 37
Simei Lin, Jia Meng, Fei Li, et al.
Food & Function (2022) Vol. 13, Iss. 24, pp. 12619-12631
Closed Access | Times Cited: 37
Gout and Cardiovascular Disease: Mechanisms, Risk Estimations, and the Impact of Therapies
Mariano Andrés
Gout Urate and Crystal Deposition Disease (2023) Vol. 1, Iss. 3, pp. 152-166
Open Access | Times Cited: 13
Mariano Andrés
Gout Urate and Crystal Deposition Disease (2023) Vol. 1, Iss. 3, pp. 152-166
Open Access | Times Cited: 13
Xanthine oxidase inhibitors treatment or discontinuation effects on mortality: evidence of xanthine oxidase inhibitors withdrawal syndrome
Masanari Kuwabara, Michikazu Nakai, Yoko Sumita, et al.
Frontiers in Pharmacology (2024) Vol. 14
Open Access | Times Cited: 4
Masanari Kuwabara, Michikazu Nakai, Yoko Sumita, et al.
Frontiers in Pharmacology (2024) Vol. 14
Open Access | Times Cited: 4
Current updates and future perspectives in uric acid research, 2024
Masanari Kuwabara, Ryusuke Ae, Koki Kosami, et al.
Hypertension Research (2024)
Closed Access | Times Cited: 4
Masanari Kuwabara, Ryusuke Ae, Koki Kosami, et al.
Hypertension Research (2024)
Closed Access | Times Cited: 4
Epidemiology and treatment-related concerns of gout and hyperuricemia in Korean
Joong Kyong Ahn
Journal of Rheumatic Diseases (2023) Vol. 30, Iss. 2, pp. 88-98
Open Access | Times Cited: 10
Joong Kyong Ahn
Journal of Rheumatic Diseases (2023) Vol. 30, Iss. 2, pp. 88-98
Open Access | Times Cited: 10
Colchicine and cardiovascular protection in gout: unresolved questions – Authors' reply
Edoardo Cipolletta, Laila J. Tata, Abhishek Abhishek
The Lancet Rheumatology (2025)
Closed Access
Edoardo Cipolletta, Laila J. Tata, Abhishek Abhishek
The Lancet Rheumatology (2025)
Closed Access
Cardiovascular Events During Treatment With Xanthine Oxidoreductase Inhibitors in Patients With Gout and Hyperuricemia in Japan ― A JMDC Claims Database Study ―
Kazuomi Kario, Seigo Akari, Hiroshi Kanegae
Circulation Reports (2025) Vol. 7, Iss. 3, pp. 183-190
Open Access
Kazuomi Kario, Seigo Akari, Hiroshi Kanegae
Circulation Reports (2025) Vol. 7, Iss. 3, pp. 183-190
Open Access
The Hong Kong Society of Rheumatology consensus recommendations for the management of gout
Ronald ML Yip, TT Cheung, Ho So, et al.
Clinical Rheumatology (2023) Vol. 42, Iss. 8, pp. 2013-2027
Open Access | Times Cited: 4
Ronald ML Yip, TT Cheung, Ho So, et al.
Clinical Rheumatology (2023) Vol. 42, Iss. 8, pp. 2013-2027
Open Access | Times Cited: 4
Efficacy and safety of the urate-lowering agent febuxostat in chronic heart failure patients with hyperuricemia: results from the LEAF-CHF study
Takashi Yokota, Shintaro Kinugawa, Arata Fukushima, et al.
Heart and Vessels (2024)
Closed Access | Times Cited: 1
Takashi Yokota, Shintaro Kinugawa, Arata Fukushima, et al.
Heart and Vessels (2024)
Closed Access | Times Cited: 1
Urate-lowering therapy following a treat-to-target continuation strategy compared to a treat-to-avoid-symptoms discontinuation strategy in gout patients in remission (GO TEST Finale): study protocol of a multicentre pragmatic randomized superiority trial
Iris Rose Peeters, Alfons A den Broeder, William J. Taylor, et al.
Trials (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 3
Iris Rose Peeters, Alfons A den Broeder, William J. Taylor, et al.
Trials (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 3
¿Debemos manejar la hiperuricemia asintomática para proteger al riñón?
Alberto Francisco Rubio-Guerra, Carolina Guerrero García
Revista Colombiana de Nefrología (2023) Vol. 10, Iss. 1
Open Access | Times Cited: 2
Alberto Francisco Rubio-Guerra, Carolina Guerrero García
Revista Colombiana de Nefrología (2023) Vol. 10, Iss. 1
Open Access | Times Cited: 2
Regional variations of cardiovascular risk in gout patients: a nationwide cohort study in Korea
Hyun Jung Kim, Byeongzu Ghang, Jinseok Kim, et al.
Journal of Rheumatic Diseases (2023) Vol. 30, Iss. 3, pp. 185-197
Open Access | Times Cited: 2
Hyun Jung Kim, Byeongzu Ghang, Jinseok Kim, et al.
Journal of Rheumatic Diseases (2023) Vol. 30, Iss. 3, pp. 185-197
Open Access | Times Cited: 2
Uric Acid and Kidney
Manisha Sahay
Journal of Renal Nutrition and Metabolism (2023) Vol. 8, Iss. 1, pp. 24-29
Closed Access
Manisha Sahay
Journal of Renal Nutrition and Metabolism (2023) Vol. 8, Iss. 1, pp. 24-29
Closed Access
